ASIAMEDIC LIMITED

(Incorporated in the Republic of Singapore)
(Company Registration No. 197401556E)

PROPOSED SUBSCRIPTION OF 5,000,000 NEW ORDINARY SHARES IN THE CAPITAL OF ASIAMEDIC LIMITED – RECEIPT OF LISTING AND QUOTATION NOTICE

Unless otherwise defined or if the context otherwise requires, capitalised terms used herein shall have the same meanings ascribed to them in the Company's announcement dated 4 September 2026 (the "**Announcement**").

The Board of Directors of AsiaMedic Limited (the "**Company**") refers to the Announcement and is pleased to announce that the Company has received the listing and quotation notice (the "**LQN**") from the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") on 17 September 2026 in respect of the listing and quotation of 5,000,000 new ordinary shares in the capital of the Company (the "**Subscription Shares**") pursuant to the Proposed Subscription.

The LQN in respect of the Subscription Shares is subject to the following:

(i) compliance with the SGX-ST's listing requirements, including Rules 704(30) and 1204(22) of the Listing Manual (Section B: Rules of Catalist) of the SGX-ST (the "**Catalist Rules**") in relation to announcing the use of proceeds; and

(ii) the Subscription Shares have to be placed out within seven (7) market days from the date of the LQN.

The Company hereby confirms that:

(a) the Subscription Shares will be issued out of a general share issue mandate pursuant to Rule 806 of the Catalist Rules;

(b) the Subscription Shares are not being placed to any person specified in Rule 812 of the Catalist Rules;

(c) the issuance of the Subscription Shares will not transfer a controlling interest in the Company; and

(d) the issuance of the Subscription Shares is not priced at more than 10% discount to the applicable benchmarks as set out under the Catalist Rules,

accordingly, no shareholders' approval is required for the Proposed Subscription.

The LQN granted by the SGX-ST is not an indication of the merits of the Company, its subsidiaries, the ordinary shares in the capital of the Company (including the Subscription Shares), and the Proposed Subscription.

The Company will update Shareholders on the progress of the Proposed Subscription through further announcement(s) in due course.

By Order of the Board

Foo Soon Soo (Ms)
Company Secretary

17 September 2026

This announcement has been reviewed by the Company's Sponsor, Xandar Capital Pte Ltd. It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "SGX-ST") and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement. The contact person for the Sponsor is Ms Pauline Sim (Registered Professional, Xandar Capital Pte Ltd) at 3 Shenton Way, #24-02 Shenton House, Singapore 068805. Telephone number: (65) 6319 4954.